LETTER: Patent medicine for genes

Godehard Nowak
Wednesday 20 September 1995 18:02 EDT
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

From Mr Godehard Nowak

Sir: In his article looking forward to the public hearing of the European patent system, at the European Patent Office (EPO) in Munich, Tom Wilkie implies that the EPO is acting outside the context of public opinion [in saying that "public attitudes have changed since 1973" regarding the patenting of surgical procedures].

Mr Wilkie also states that the documents for this meeting have been circulated "exclusively within the community of patent lawyers and companies interested in protecting their intellectual property".

In fact, invitations to comment on the European Patent Organisation's proposals for strategies went out to nearly 250 newspapers and journals in the 17 member states of the organisation (although the Independent was the only one of the newspapers to contribute a comment).

These invitations to comment were directed not only to the users of the patent system and the press, but also to ministries of technology and research, and other international organisations, professional associations, think tanks and universities or research institutes that specialise in intellectual property matters.

Their statements formed part of the materials for discussion at the hearing.

Yours faithfully,

Godehard Nowak

Director

Public Relations

European Patent Office

Munich

14 September

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in